Navigation Links
Cowen Group, Inc. Announces 2008 First Quarter Results
Date:5/8/2008

sal) expense related

to IPO awards (4.2) 2.5

Adjusted operating (loss) income (1.9) 5.1

(Benefit) provision for income taxes (1.3) 2.2

Adjusted net operating (loss)

income $(0.6) $2.9

Q1:08 Q1:07 Q4:07

(dollars in millions)

Reconciliation of Brokerage Revenue

to Core Brokerage Revenue

Brokerage revenue $38.1 $45.2 $35.1

Exclusion of the loss (income)

from warrants, asset management

seed funds, restricted

stock received in connection

with the demutualization of

certain exchanges and mutual

fund investments held as a hedge

against legacy deferred compensation

obligations 1.6 (5.0) 1.6

Core brokerage revenue $39.7 $40.2 $36.7

Non-GAAP Financial Measures

We have reported in this press release our adjusted net operating loss for the quarters ended March 31, 2008 and 2007 on a non-GAAP basis by:

-- excluding the non-cash compensation (reversal) expense associated with

equity awards granted in connection with our IPO; and

-- calculating the (benefit) provision for income taxes using the

effective tax rate for the period.

Management believes that the grant of equity awards in connection with our IPO was an extraordinary, non-recurring event. We expect that additional equity will be granted in connection with our compensation, hiring and retention practices, and therefore will be included in our compensation and benefits expense to revenue ratio. Historically, the expense associated with all equity awards, other that the IPO awards, have been included in
'/>"/>

SOURCE Cowen Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ISTA Pharmaceuticals Engages Cowen as Financial Advisor
2. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
3. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
4. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
5. MannKind to Present at the Cowen and Company Healthcare Conference
6. Johnson & Johnson to Participate in the 28th Annual Cowen & Company Health Care Conference
7. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
8. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
9. XTENT to Present at Cowen and Companys 28th Annual Health Care Conference
10. Iomai CEO to Speak at Cowen and Company Health Care Conference on Monday, March 17
11. Edwards Lifesciences to Present at the Cowen and Company Annual Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... Long-term survivors of testicular cancer who wer...re severe side effects, including neurological sid... were not treated with chemotherapy, according to ...ournal of the National Cancer Institute . , Mari...aukeland University Hospital, in Bergen, Norway, a...
(Date:11/25/2009)...But study follow-up period was too short to draw d...EDNESDAY, Nov. 25 (HealthDay News) -- In diabetic ...ears to be no difference in outcomes at one year w...sty with stenting, British researchers report. ,...or diabetic patients with coronary artery disease....
(Date:11/25/2009)...Survivors often plagued by neurological symptoms, ...lthDay News) -- Neurological side effects are amon...ors of testicular cancer who were treated with cis..., The study included 1,409 Norwegian men treate...d 1994 who took part in a follow-up survey conduct...
(Date:11/25/2009)...,, LittleImprovementShownforthe4thStraightY...e/-- Today,LungCancerAlliance-Georgia(LCA-GA)issu...sanassessmentofprogressbeingmadeagainstthislethald...ncerAlliance(LCA),theonlynationalorganizationdedic...elivingwithoratriskforlungcancer. ,, (Logo: htt...
(Date:11/25/2009)...In mice, disks placed under the skin kill tumor ce...(HealthDay News) -- A cancer vaccine delivered in ...rs in mice, a new study reports. , The method u...at are loaded with tumor-specific antigens and imp...em to attack tumors. The Harvard University scient...
Breaking Medicine News(10 mins):Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
... R.D. helps Americans find healthier choices-- , ...ician Ashley Koff is proud to announce Ashley Koff...r nutrition for optimal health. After several year...world of nutrition, designed a tool to meet all th...
...rting to Embrace Use of Targeted Agents Despite Th... Resources , , WALTHAM, Mass., April 28 Decisio...nd advisory firms focusing on pharmaceutical and h...ine) will dominate the Indian colorectal cancer dr...
...8 Healthy Life Laboratories has announced the rel...diabetes patients and healthcare professionals - t... of its kind for use on iPhone and iPod Touch ...e control is essential for diabetics. Home glucos...
...d during American Urological Association Annual Me...ride (Avodart), a commonly prescribed drug to trea...lower the risk of prostate cancer by 23 percent in...ociation (AUA) Annual Meeting in Chicago. Data fro...
...awa Hospital purchases system to reduce , workload...rgency rooms , , OTTAWA, April 28 /PRNewswire/ - ...outreach solutions, today announced the sale of it...al Association Journal shows that CallAssure was e...
...e potential to preserve vision for millions , , B... people will suffer from age-related macular degen...nd from the disease, according to the U.S. Centers...iversity of Alabama Birmingham (UAB) indicates th...
Other Medicine News:Health News:Introducing 'Ashley Koff Approved' (AKA): the Stamp of Nutrition for Optimal Health 2Health News:Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013 2Health News:Healthy Life Laboratories Announces Hemoglobin A1c iPhone Application 2Health News:Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk 2Health News:Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk 3Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 2Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 3Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 4Health News:New Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement 2
(Date:11/25/2009)...RNewswire-FirstCall/--HeartWareInternational,Inc.(...roflessinvasive,miniaturizedcirculatorysupporttech...failure,todayannouncedthatitisscheduledtomakeaninv...CareConferenceat8:00amESTonWednesday,December2,200...December1-2. ,, AlivewebcastoftheCompany,sprese...
(Date:11/24/2009)...rstCall/--Endologix,Inc.(Nasdaq: ELGX ),developero...ouncedtodaythatithasfiledamotiontostay,ordiscontin...ughtagainstitinOctober2009byCook,Inc.Themotionwasf...ndiana. ,, Endologixhasrequestedthatthestayrema...fice(USPTO)conductsproceedingstore-examinethetwopa...
(Date:11/24/2009)...4/PRNewswire/-- EisaiInc.andPfizerIncannouncedtod...ptedforreviewEisai,sNewDrugApplication(NDA)foronce...)tabletsforthetreatmentofmoderatetosevereAlzheimer...23mgofdonepezilHClinanextendedrelease,matrix-typet...eofthedrug.TheNDAisbasedonahead-to-headclinicalstu...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3DST Systems Inc Announces Exchange Transaction Involving 4 125 25 Series A Convertible Senior Debentures 58653 1DST Systems Inc Announces Exchange Transaction Involving 4 125 25 Series A Convertible Senior Debentures 58653 2Medicago begins human clinical testing with its avian flu pandemic vaccine 14315 1Medicago begins human clinical testing with its avian flu pandemic vaccine 14315 2Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 5145 1Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 5145 2Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 5145 3Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 5145 4
Inorganic Phosphorus Color Reagent
Amylase (EPS-G7, kinetics)
Amylase Reagent
Calcium Reagent Set
Medicine Products: